For the Inventor, By the Inventor

Enter assignee name

Kyowa Kirin Co., Ltd.

USPTO Granted Patents = 46

% Expired Patents = 10.9

CIPO Patents = 5

EPO Patents = 40

Trademarks = 24

Forward Citations = 19

Loading Chart...

Loading Chart...

126 inventors (with patents filed for the assignee):

Shinya Ogawa (6 out of 11 patents)

Nobuaki Takahashi (5 out of 84 patents)

Ryosuke Nakano (5 out of 6 patents)

4. Emil D Kakkis (4 out of 45 patents)

5. Javier San Martin (4 out of 4 patents)

6. Tomohiro Sudo (4 out of 4 patents)

7. Sayaka Maeda (4 out of 5 patents)

8. Tomohiro Danjo (3 out of 3 patents)

9. Shintaro Hosoe (3 out of 7 patents)

10. Yuji Ito (3 out of 17 patents)

11. Akifumi Kato (3 out of 4 patents)

12. Kaname Kimura (3 out of 4 patents)

13. Masakazu Homma (3 out of 4 patents)

14. Takahiro Nakajima (3 out of 10 patents)

15. Takashi Imaeda (3 out of 5 patents)

Core Competencies:

Monoclonal Antibodies

Bispecific Antibodies

Nucleic Acid Conjugates

Pharmaceutical Compositions

Anticancer Compounds

IL-2 Variants

Cell Adhesion Molecules

Hypophosphatemic Disorders

Radiation Damage Treatment

Protein Stabilization

Cationic Lipids

Thiazole Derivatives

46 patents: Sort by Forward Citations

1. 12466891 - BISPECIFIC ANTIBODY BINDING TO CD40 AND GPC3 (2025-11-11),

2. 12358976 - Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d (2025-07-15),

3. 12319741 - Human monoclonal antibody human CD134 (OX40) and methods of making and using same (2025-06-03),

4. 12297268 - Antibody which binds to myelin oligodendrocyte glycoprotein (2025-05-13),

5. 12280118 - IL-2 variant (2025-04-21),

6. 12258413 - Bispecific antibody binding to TfR (2025-03-25),

7. 12251446 - Nucleic acid conjugate (2025-03-18),

8. 12234292 - FN14 antibodies and uses thereof (2025-02-25),

9. 12187803 - Bispecific antibody that binds to CD116 and CD131 (2025-01-07),

10. 12054494 - Compound with anticancer activity (2024-08-06),

11. 11999788 - Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody (2024-06-04),

12. 11970531 - Methods for treating hypertension using an anti-BMP10 monoclonal antibody or fragment thereof (2024-04-30),

13. 11965035 - Antibody binding to chondroitin sulfate proteoglycan 5 (2024-04-23),

14. 11951103 - Pharmaceutical composition (2024-04-09),

15. 11912775 - Anti-human CCR1 monoclonal antibody (2024-02-27),

Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company that contributes to the health and well-being of people around the world. With a focus on three main areas - oncology, nephrology, and immunology/allergy - Kyowa Kirin strives to improve the lives of patients through innovative medical advancements. Through research, development, and manufacturing of pharmaceuticals, the company aims to provide high-quality treatments and therapies that address unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Kyowa Kirin Co., Ltd.

46 Patents

#835 in Tokyo

#1,799 in Japan

#15,070 in the World

Kyowa Kirin Co., Ltd.

Forward Citations = 19

126 inventors:

Shinya Ogawa (6 out of 11 patents)

Nobuaki Takahashi (5 out of 84 patents)

Ryosuke Nakano (5 out of 6 patents)

4. Emil D Kakkis (4 out of 45 patents)

5. Javier San Martin (4 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…